文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

欧洲耐利福平结核病患者对贝达喹啉、普托马尼、利奈唑胺和莫西沙星(BPaL(M))方案药物及耐药检测的可及性

Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
PubMed 文献 · Clin Microbiol Infect · 2024-03-13

该研究通过结构化问卷于2023年9月至11月调查了世界卫生组织欧洲区域54个国家中44个国家的结核病网络欧洲试验组代表,评估BPaL(M)方案药物及药敏试验的可及性。结果显示仅52.3%的国家可获得全部四种药物,47.7%的国家可进行全部药物的药敏试验,普托马尼的可及性最低。

要点

  • 44国中仅23国(52.3%)可获得BPaL(M)方案全部药物。
  • 普托马尼药物可及性为24/44(54.5%),药敏试验可及性为21/44(47.7%)。
  • 作者认为欧洲迫切需要公平获得新方案并快速扩大药敏试验。

核心结论

  • 仅约半数参与调查的国家临床医生可获得BPaL(M)方案全部药物。
  • 不到半数国家可完成BPaL(M)全部药物的药敏试验,主要因普托马尼药敏试验可及性低。
  • 作者认为欧洲迫切需要公平获得新方案,并快速扩大药敏试验尤其是普托马尼药敏试验,以防止耐药性未被发现地传播。

研究设计与样本

  • 结核病网络欧洲试验组代表于2023年9月至11月通过结构化问卷进行调查。
  • 覆盖世界卫生组织欧洲区域54个国家中的44个国家。
  • 调查内容为BPaL(M)方案药物及药敏试验的可及性。

主要发现

  • 44国中,普托马尼可及24国(54.5%),贝达喹啉42国(95.5%),利奈唑胺43国(97.7%),莫西沙星43国(97.7%)。
  • 44国中,23国(52.3%)可获得BPaL(M)方案全部药物。
  • 44国中,普托马尼药敏试验可及21国(47.7%),贝达喹啉37国(84.1%),利奈唑胺40国(90.9%),莫西沙星41国(93.2%)。
  • 44国中,21国(47.7%)可进行BPaL(M)方案全部药物的药敏试验,包括普托马尼药敏试验仅在专门实验室可及的国家。
  • 在可获得相应药物的国家中,药敏试验可及性为:普托马尼21/24(87.5%),贝达喹啉37/42(88.1%),利奈唑胺40/43(93.1%),莫西沙星41/43(95.3%)。

关键数值与推荐

  • 世界卫生组织推荐基于两项高效低毒试验结果使用贝达喹啉、普托马尼、利奈唑胺和莫西沙星(BPaL(M))方案6个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Multidrug-resistant/rifampicin-resistant tuberculosis is a major obstacle to successful tuberculosis control. The recommendation by the WHO to use bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) for 6 months, based on results of two trials with high efficacy and low toxicity, has revolutionized treatment options. METHODS: In this study, representatives of the Tuberculosis Network European Trials group in 44 of 54 countries of the WHO Europe region documented the availability of the medicines and drug susceptibility testing (DST) of the BPaL(M) regimen through a structured questionnaire between September and November 2023. RESULTS: In total, 24 of 44 (54.5%), 42 of 44 (95.5%), 43 of 44 (97.7%), and 43 of 44 (97.7%) countries had access to pretomanid, bedaquiline, linezolid, and moxifloxacin, respectively. Overall, 23 of 44 (52.3%) countries had access to all the drugs composing the BPaL(M) regimen. In total, 21 of 44 (47.7%), 37 of 44 (84.1%), 40 of 44 (90.9%), and 41 of 44 (93.2%) countries had access to DST for pretomanid, bedaquiline, linezolid, and moxifloxacin, respectively. Overall, DST was available for all medicines composing the BPaL(M) regimen in 21 of 44 (47.7%) countries, including countries where pretomanid DST was available at specialized laboratories. The availability of DST for the drugs the countries had access to, varied from 87.5% to 95.3% (pretomanid 21 of 24 (87.5%), bedaquiline 37 of 42 (88.1%), linezolid 40 of 43 (93.1%) and moxifloxacin 41 of 43 (95.3%)). DISCUSSION: In only about half of the countries participating in the survey, clinicians had access to all the BPaL(M) regimen drugs. A complete DST for the BPaL(M) medicines was possible in less than half of the countries, because of the low accessibility of DST for pretomanid. Equal access to new regimens is urgently needed in Europe and a rapid scale up of DST, especially for pretomanid, is important to prevent unnoticed spread of drug resistance.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Günther G, Guglielmetti L, Kherabi Y, et al. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024. PMID: 38490355. doi:10.1016/j.cmi.2024.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。